Skip to content

Study · Animal study (in vivo) · rat · 2019

4 results

Subchronic cerebrolysin treatment alleviates cognitive impairments and dendritic arborization alterations of granular neurons in the hippocampal dentate gyrus of rats with temporal lobe epilepsy.

Zamudio SR, Pichardo-Macías LA, Díaz-Villegas V, Flores-Navarrete IL, Guzmán-Velázquez S

Epilepsy & behavior : E&B15 Jun 2019Cited by 12 (Europe PMC)

PMID31207446 (opens in a new tab)DOI10.1016/j.yebeh.2019.05.025 (opens in a new tab)PepBankPUB-31207446
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In epileptic rats, cerebrolysin-treated animals had seizure frequency similar to vehicle-treated animals.

    In plain wordsIn rats with epilepsy, seizure frequency was similar with cerebrolysin and vehicle.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedSecondarily generalized seizure frequency
    Study

    ratn: not reported in source

    Lithium-pilocarpine temporal lobe epilepsy in male Wistar rats
    Comparator
    Vehicle-treated epileptic rats
    Outcome group
    Seizures · Nervous system and cognition
    Studied dose
    538 mg/kg · intraperitoneal · 5 consecutive days per week for 3 weeksAs given in this study (rat).

    Source sentences

    Summary
    Epileptic animals treated with this agent exhibited secondarily generalized seizures similar in frequency and intensity to those of epileptic animals treated only with vehicle.
    2 context sentences
    Summary · context
    Temporal lobe epilepsy (lithium-pilocarpine model) was induced in male Wistar rats (weight, 250-300 g).
    Summary · context
    Two epileptic groups were studied, in which CBL (538 mg/kg) or vehicle was administered intraperitoneally for 5 consecutive days per week for 3 weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In epileptic rats, cerebrolysin-treated animals had seizure intensity similar to vehicle-treated animals.

    In plain wordsIn rats with epilepsy, seizure intensity was similar with cerebrolysin and vehicle.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedSecondarily generalized seizure intensity
    Study

    ratn: not reported in source

    Lithium-pilocarpine temporal lobe epilepsy in male Wistar rats
    Comparator
    Vehicle-treated epileptic rats
    Outcome group
    Seizures · Nervous system and cognition
    Studied dose
    538 mg/kg · intraperitoneal · 5 consecutive days per week for 3 weeksAs given in this study (rat).

    Source sentences

    Summary
    Epileptic animals treated with this agent exhibited secondarily generalized seizures similar in frequency and intensity to those of epileptic animals treated only with vehicle.
    2 context sentences
    Summary · context
    Temporal lobe epilepsy (lithium-pilocarpine model) was induced in male Wistar rats (weight, 250-300 g).
    Summary · context
    Two epileptic groups were studied, in which CBL (538 mg/kg) or vehicle was administered intraperitoneally for 5 consecutive days per week for 3 weeks.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In epileptic rats, cerebrolysin appeared to attenuate dendritic deterioration in hippocampal granular neurons.

    In plain wordsIn rats with epilepsy, cerebrolysin appeared to reduce dendritic deterioration compared with vehicle.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseGranular neuron dendritic deterioration
    Study

    ratn: not reported in source

    Lithium-pilocarpine temporal lobe epilepsy in male Wistar rats
    Comparator
    Vehicle-treated epileptic rats
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    538 mg/kg · intraperitoneal · 5 consecutive days per week for 3 weeksAs given in this study (rat).

    Source sentences

    Summary
    However, when analyzing dendritic morphology of hippocampal granular neurons in these animals, CBL appeared to attenuate dendritic deterioration caused by epilepsy, which was associated with improved cognitive performance of the CBL-treated animals in the BMT compared with vehicle-treated epileptic rats.
    2 context sentences
    Summary · context
    Temporal lobe epilepsy (lithium-pilocarpine model) was induced in male Wistar rats (weight, 250-300 g).
    Summary · context
    Two epileptic groups were studied, in which CBL (538 mg/kg) or vehicle was administered intraperitoneally for 5 consecutive days per week for 3 weeks.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In epileptic rats, cerebrolysin improved Barnes maze cognitive performance versus vehicle, associated with attenuated dendritic deterioration.

    In plain wordsIn rats with epilepsy, cerebrolysin improved maze test performance compared with vehicle.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseBarnes maze cognitive performance
    Study

    ratn: not reported in source

    Lithium-pilocarpine temporal lobe epilepsy in male Wistar rats
    Comparator
    Vehicle-treated epileptic rats
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    538 mg/kg · intraperitoneal · 5 consecutive days per week for 3 weeksAs given in this study (rat).

    Source sentences

    Summary
    However, when analyzing dendritic morphology of hippocampal granular neurons in these animals, CBL appeared to attenuate dendritic deterioration caused by epilepsy, which was associated with improved cognitive performance of the CBL-treated animals in the BMT compared with vehicle-treated epileptic rats.
    2 context sentences
    Summary · context
    Temporal lobe epilepsy (lithium-pilocarpine model) was induced in male Wistar rats (weight, 250-300 g).
    Summary · context
    Two epileptic groups were studied, in which CBL (538 mg/kg) or vehicle was administered intraperitoneally for 5 consecutive days per week for 3 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.